Implications for policy makers
prostate cancer
PROSTATE CANCER
Policy makers must consider whether screening programmes are affordable within the budget available. We have shown in the case of PSA testing for prostate cancer that this is potentially questionable in the UK context. However, a budget impact analysis does not supply evidence about the value for money that the programme offers, so policy makers should consider our results alongside effectiveness and cost-effectiveness evidence [